Literature DB >> 8780581

Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver.

T Knittel1, P Fellmer, G Ramadori.   

Abstract

BACKGROUND & AIMS: Plasminogen activator inhibitor type 1 (PAI-1) plays a crucial role in the regulation of extracellular matrix-degrading enzymes and in the production of fibrogenic mediators such as transforming growth factor beta through inhibition of plasminogen activation. Because hepatic stellate cells (HSCs), the principal matrix-producing cell of the liver, might also affect extracellular matrix degradation and growth factor activation, the aim of this study was to analyze PAI-1 expression and its regulation in HSCs compared with other liver cells.
METHODS: PAI-1 synthesis of liver cells at different time points of primary culture was studied by immunoprecipitation of endogenously labeled proteins followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and by Northern blotting.
RESULTS: Among the various types of liver cells, PAI-1 protein and specific transcripts were present in HSCs and endothelial cells, and no major PAI-1 synthesis was detected in Kupffer cells and hepatocytes. Transforming growth factor beta 1, tissue plasminogen activator, and dexamethasone increased PAI-1 production in HSCs.
CONCLUSIONS: Apart from their role as the principal connective tissue-producing cell of the liver, HSCs might regulate extracellular matrix accumulation by modulating the activities of matrix-degrading enzymes and fibrogenic mediators through the production of PAI-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780581     DOI: 10.1053/gast.1996.v111.pm8780581

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Role of the Ets-1 transcription factor during activation of rat hepatic stellate cells in culture.

Authors:  T Knittel; D Kobold; J Dudas; B Saile; G Ramadori
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  Is liver fibrosis reversible?

Authors:  R C Benyon; J P Iredale
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 3.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  Expression of macrophage inflammatory protein-1alpha in Kupffer cells following liver ischemia or reperfusion injury in rats.

Authors:  Wei Ma; Zuo-Ren Wang; Lei Shi; Yue Yuan
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

5.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

6.  Monitoring coagulation proteins during progression of liver disease.

Authors:  Mohamed Hessien; Mohamed Ayad; Wafaa M Ibrahim; Batoul Izz ulArab
Journal:  Indian J Clin Biochem       Date:  2014-04-19

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 8.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

Review 9.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

10.  Expression of ECM proteins fibulin-1 and -2 in acute and chronic liver disease and in cultured rat liver cells.

Authors:  Fabio Piscaglia; József Dudás; Thomas Knittel; Paola Di Rocco; Dominik Kobold; Bernhard Saile; Maria Assunta Zocco; Rupert Timpl; Giuliano Ramadori
Journal:  Cell Tissue Res       Date:  2009-07-17       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.